ClinicalTrials.gg

Program

gatuzosiran

A development code. Also written as “GSK4532990”.

In GlaxoSmithKline's pipeline, HSD17B13 RNA interference. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Diseases, Alcoholic, led by GlaxoSmithKline.

Furthest: phase 2, since Oct 13, 20223 company-led studies, 1 open or runningNext primary completion: Nov 26, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline31 open or runningphase 2since Oct 13, 2022Oct 13, 2022Nov 26, 2027phase 2 · NCT06613698
  • Named in GlaxoSmithKline’s own pipeline as gatuzosiran GSK4532990, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2022First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05583344 · 284 enrolled · United States, Argentina, Australia and more
  2. Oct 23, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06104319 · 61 enrolled · United States
  3. Sep 23, 2024Phase 2 study in Liver Diseases, AlcoholicNCT06613698 · 350 planned · United States, Argentina, Australia and more

Ahead

  1. Nov 26, 2027Primary completion: phase 2 study in Liver Diseases, AlcoholicNCT06613698

TargetBeta

“HSD17B13 RNA interference”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06613698Liver Diseases, Alcoholic · United States, Argentina, Australia and more2RecruitingNov 26, 2027350
NCT06104319Non-alcoholic Fatty Liver Disease · United States2CompletedSep 23, 202561
NCT05583344Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more2CompletedJan 31, 2026284

How it is read

Names in the registry

  • “GSK4532990”, 3 entries

Codes read as this program: GSK4532990.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.